Journal article
Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer
M Alberto, A Yim, N Papa, S Siva, J Ischia, K Touijer, JA Eastham, D Bolton, M Perera
Frontiers in Oncology | FRONTIERS MEDIA SA | Published : 2022
Abstract
Oligometastatic prostate cancer (OMPC) has been proposed as an intermediary state between localised disease and widespread metastases, with varying definitions including 1, 3, or ≤5 visceral or bone metastasis. Traditional definitions of OMPC are based on staging with conventional imaging, such as computerised tomography (CT) and whole-body bone scan (WBBS). Novel imaging modalities such as prostate-specific membrane antigen positron emission tomography (PSMA PET) have improved diagnostic utility in detecting early metastatic prostate cancer (PC) metastases compared with conventional imaging. Specifically, meta-analytical data suggest that PSMA PET is sensitive in detecting oligometastatic d..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by the Sidney Kimmel Center for Prostate and Urologic Cancers at MSK and the NIH/NCI Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748). Marlon Perera is sponsored by the Australian-America Fulbright Commission administered through a 2021-2022 Fulbright Future Scholarship funded by The Kinghorn Foundation.